Prior to our 1,100-patient autism clinical study, Children’s Autism Metabolome Project (CAMP), we conducted two smaller studies to learn about the connection between metabolism and autism.
Both studies were conducted in collaboration with the University of California-Davis MIND Institute (Medical Investigation of Neurodevelopmental Disorders). Autism expert Dr. David Amaral was the Principal Investigator.
TD = typically-developing children
ASD = children diagnosed with autism spectrum disorder
Accuracy reflects the percentage of children who could be properly classified as ASD or TD, based on the biomarkers found in the blood test. The metabolites identified contain both new biomarkers of ASD as well as some known biomarkers.
The results of our initial studies motivated us to explore the connection between metabolism and autism more thoroughly. It was clear we were on to something. These studies gave us confidence to work on a larger study with the understanding that we had discovered a new way to think about—and possibly, in the future, diagnose—autism spectrum disorder.
Next Stop: Enter Children’s Autism Metabolome Project (CAMP)
With CAMP, the NeuroPointDX team was interested in answering many questions about autism and metabolism, including:
Can we test fewer metabolites and reach the same conclusions that we did in the initial studies?
Can we identify a group of metabolic subtypes that indicate ASD?
Our bioinformatics team found that metabolic subtypes could be identified if metabolites are viewed in relation to each other, using algorithms, developed in-house.